Characterizing the Experience of Tapentadol Nonmedical Use: Mixed Methods Study

Abstract

Background The prevalence of abuse, diversion, and web-based endorsement of tapentadol (extended-release [ER], immediate-release [IR]) has been characterized as low compared with other prescription opioids. Little is known about individual experience with tapentadol nonmedical use (NMU). Objective This study aims to pilot web-based survey technologies to investigate the motivation for tapentadol NMU, sources of procurement, routes of administration, tampering methods, doses used, and impressions of tapentadol products (Nucynta and Nucynta ER). Methods Recruitment flyers and banner advertisements were placed on the Bluelight website [DragonByte Technologies Ltd] with a link to a web-based survey (Qualtrics) designed to query about individuals’ lifetime tapentadol NMU. This web-based survey was followed by an interactive web-based chat (Cryptocat) with respondents who were willing to be contacted. Respondents were queried about sources for obtaining tapentadol, motives for use, routes of administration, tampering methods, drugs used in combination, tablet strengths and dosages, and reasons for continued or discontinued use. Desirability and attractiveness for NMU was rated. Results Web-based recruitment successfully attracted difficult-to-find study participants. A total of 78 participants reported that tapentadol was obtained from friends and family (ER 11/30, 37%; IR 18/67, 27%), the internet (ER 11/30, 37%; IR 12/67, 18%) or participants’ own prescriptions from a doctor (ER 9/30, 30%; IR 17/67, 25%). It was used nonmedically for pain relief (ER 18/30, 60%; IR 33/67, 49%) and multiple psychotropic effects, including relaxation (ER 13/30, 43%; IR 29/67, 43%), reduction in depression or anxiety (ER 7/30, 23%; IR 30/67, 45%), or getting high (ER 12/30, 40%; IR 33/67, 49%). Tapentadol was primarily swallowed (ER 22/30, 73%; IR 55/67, 82%), although snorting (ER 2/30, 7%; IR 8/67, 12%) and injection (ER 2/30, 7%; IR 5/67, 8%) were also reported. The preferred dose for NMU was 100 mg (both ER and IR). The participants reported tapentadol use with benzodiazepines (ER 12/21, 57%; IR 28/47, 60%). Most participants had discontinued tapentadol NMU at the time of survey completion (ER 22/30, 73%; IR 55/67, 82%). Reasons for discontinued ER NMU included side effects (10/22, 46%) and lack of effective treatment (10/22, 46%). Reasons for discontinued IR NMU included lack of access (26/55, 47%) and better NMU options (IR 21/55, 38%). Few individuals were willing to divulge identifying information about themselves for the interactive chat (8/78, 10%), demonstrating the strength of anonymous, web-based surveys. Interactive chat supported the survey findings. A subgroup of participants (4/78, 5%) reported hallucinogenic side effects with high doses. Conclusions Web-based surveys can successfully recruit individuals who report drug NMU and those who are difficult to find. Tapentadol NMU appears to occur primarily for pain relief and for its psychotropic effects. Although it was liked by some, tapentadol did not receive a robust pattern of endorsement for NMU.

Which Social Media Platforms Provide the Most Informative Data for Monitoring the Opioid Crisis?

“…However, researchers have previously used Pinterest and TikTok to study portrayals of drugs other than opioids (155)(156)(157)(158)(159)(160)(161)(162). Researchers have used Bluelight in the context of recruiting participants for studies related to opioid use (163,164). Our PubMed query returned no results related to opioid research for LinkedIn.…”

Assessing the risks of abuse of opioids in real-world data

“…Очень интересные результаты веб-опроса, посвящённого немедицинскому применению тапентадола, представлены в статье Vosburg Suzanne K, Dailey-Govoni T, Beaumont J et al [26] [27]. Сообщения собирали с помощью исследовательской программы веб-мониторинга системы наблюдения за злоупотреблениями, диверсификациями и зависимостью.…”

Tramadol and Tapentadol Induce Conditioned Place Preference with a Differential Impact on Rewarding Memory and Incubation of Craving

“…A study with occasional opioid users showed that, unlike tramadol, therapeutic doses of tapentadol led exclusively to positive subject-rated effects, with faster onset and offset than other opioids, which may contribute to a greater frequency of use [ 28 , 29 ]. A recent web-based survey on tapentadol non-medical use revealed that, besides pain relief, it is consumed for multiple psychotropic effects, including relaxation, reduction in depression or anxiety, and getting high; a subgroup of participants even reported hallucinogenic side effects at higher doses [ 30 ]. Such potential to induce physical and psychological dependence, supported by rewarding and reinforcing effects comparable to those of morphine, underpinned its classification as a Schedule II substance in the USA [ 7 , 28 ].…”